Advertisement

Clinical Research in Cardiology

, Volume 100, Issue 5, pp 413–423 | Cite as

Impact of smoking on the outcome of patients treated with drug-eluting stents: 1-year results from the prospective multicentre German Drug-Eluting Stent Registry (DES.DE)

  • Mohammad A. Sherif
  • Christoph A. Nienaber
  • Ralph Toelg
  • Mohamed Abdel-Wahab
  • Volker Geist
  • Steffen Schneider
  • Jochen Senges
  • Karl-Heinz Kuck
  • Ulrich Tebbe
  • Gert Richardt
Original Paper

Abstract

Background

Cigarette smoking strongly increases morbidity and mortality from cardiovascular causes, but the relevance of smoking in patients treated with drug-eluting stents (DES) is unknown.

Aims

To assess the impact of smoking on the presentation and outcome of patients treated with DES.

Methods and results

We analyzed data from the prospective multicentre German Drug-Eluting Stent Registry (DES.DE) and identified 1,122 patients who had never smoked and 1,052 patients who were current smokers. Smokers were younger (56.5 vs. 69.4 years, p < 0.0001), more often males, with less frequent diabetes and hypertension compared to non-smokers. Smokers presented more often with acute coronary syndromes. After a mean follow-up of 12.5 months, smokers had both higher mortality (4.6 vs. 2.7%, p < 0.05) and myocardial infarction (MI) rates (4.9 vs. 3%, p < 0.01). There was no significant difference between smokers and non-smokers in the rate of target vessel revascularization (9.8 vs. 11.4%, p = 0.26). Major adverse cardiac and cerebrovascular events (defined as the composite of death, MI and stroke, MACCE) were higher in smokers (10.6 vs. 6.1%, p < 0.001). Moreover, after adjustment for baseline clinical and angiographic variables, smoking continued to be a strong independent predictor for MACCE (OR = 2.34, 95% CI 1.49–3.68). In a subgroup analysis, we found that the increased risk of smoking was most prominent in patients presenting with stable angina pectoris (OR = 3.71, 95% CI 1.24–2.57, p < 0.05). Smoking almost doubled the risk for MACCE in acute MI patients, though this did not reach statistical significance (adjusted OR = 1.91, 95% CI 0.93–3.94, p = 0.74).

Conclusion

This large multicentre DES registry provides evidence that smokers treated with DES, despite lower incidence of predisposing risk factors for atherosclerosis, experience higher rates of death and MI compared to non-smokers, particularly in the setting of stable coronary artery disease. Smoking has only marginal effects on target vessel revascularization rates in patients treated with DES.

Keywords

Drug-eluting stents Smoking Survival Registry Percutaneous coronary intervention Coronary artery disease 

Notes

Acknowledgments

Our thanks to the clinical research group at the Herz-Kreislauf Zentrum, Segeberger Kliniken GmbH, especially Mrs. Daniela Schuermann-Kuchenbrandt, Mrs. Kirsten Kassner, Mr. Guido Kassner and Mr. Marcus Ring. This work was supported by Cordis Corporation, a J&J Company and Boston Scientific Corporation. Christoph A. Nienaber and Gert Richardt received lecture fees from Cordis Corporation and Boston Scientific; both are consultants for both companies. Jochen Senges received lecture fees from Cordis. The other co-authors do not report any conflict of interest.

References

  1. 1.
    Waters D, Lesperance J, Gladstone P, Boccuzzi SJ, Cook T, Hudgin R, Krip G, Higginson L (1996) Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. CCAIT Study Group. Circulation 94:614–621PubMedGoogle Scholar
  2. 2.
    Doll R, Peto R, Wheatley K, Gray R, Sutherland I (1994) Mortality in relation to smoking: 40 years’ observations on male British doctors. BMJ 309:901–911PubMedGoogle Scholar
  3. 3.
    Ezzati M, Henley SJ, Thun MJ, Lopez AD (2005) Role of smoking in global and regional cardiovascular mortality. Circulation 112:489–497PubMedCrossRefGoogle Scholar
  4. 4.
    Franco OH, der Kinderen AJ, De Laet C, Peeters A, Bonneux L (2007) Primary prevention of cardiovascular disease: cost-effectiveness comparison. Int J Technol Assess Health Care 23:71–79PubMedCrossRefGoogle Scholar
  5. 5.
    van Domburg RT, Meeter K, van Berkel DF, Veldkamp RF, van Herwerden LA, Bogers AJ (2000) Smoking cessation reduces mortality after coronary artery bypass surgery: a 20-year follow-up study. J Am Coll Cardiol 36:878–883PubMedCrossRefGoogle Scholar
  6. 6.
    van Domburg RT, op Reimer WS, Hoeks SE, Kappetein AP, Bogers AJ (2008) Three life-years gained from smoking cessation after coronary artery bypass surgery: a 30-year follow-up study. Am Heart J 156:473–476PubMedCrossRefGoogle Scholar
  7. 7.
    Lindsay GM, Tolmie EP, Martin WM, Hutton IM, Belcher PR (2009) Smoking after coronary artery bypass: high three-year mortality. Thorac Cardiovasc Surg 57:135–140PubMedCrossRefGoogle Scholar
  8. 8.
    Hasdai D, Garratt KN, Grill DE, Lerman A, Holmes DR Jr (1997) Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med 336:755–761PubMedCrossRefGoogle Scholar
  9. 9.
    Cohen DJ, Doucet M, Cutlip DE, Ho KK, Popma JJ, Kuntz RE (2001) Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker’s paradox? Circulation 104:773–778PubMedCrossRefGoogle Scholar
  10. 10.
    Violaris AG, Thury A, Regar E, Melkert R, Serruys PW (2000) Influence of a history of smoking on short term (six month) clinical and angiographic outcome after successful coronary angioplasty. Heart 84:299–306PubMedCrossRefGoogle Scholar
  11. 11.
    Sukiennik A, Kozinski M, Debska-Kozinska K, Kubica A, Grabczewska Z, Kubica J (2007) Smokers versus non-smokers undergoing percutaneous transluminal coronary angioplasty: the impact of clinical and procedural characteristics on in-hospital mortality. Cardiol J 14:482–492PubMedGoogle Scholar
  12. 12.
    Metz L, Waters DD (2003) Implications of cigarette smoking for the management of patients with acute coronary syndromes. Prog Cardiovasc Dis 46:1–9PubMedCrossRefGoogle Scholar
  13. 13.
    Weisz G, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey TD, Rutherford BD, Mehran R, Aymong E, Lansky A, Grines CL, Stone GW (2005) Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction—the smoker’s paradox revisited. Am Heart J 150:358–364PubMedCrossRefGoogle Scholar
  14. 14.
    Kenfield SA, Stampfer MJ, Rosner BA, Colditz GA (2008) Smoking and smoking cessation in relation to mortality in women. JAMA 299:2037–2047PubMedCrossRefGoogle Scholar
  15. 15.
    Robinson K, Conroy RM, Mulcahy R (1989) When does the risk of acute coronary heart disease in ex-smokers fall to that in non-smokers? A retrospective study of patients admitted to hospital with a first episode of myocardial infarction or unstable angina. Br Heart J 62:16–19PubMedCrossRefGoogle Scholar
  16. 16.
    Nienaber CA, Akin I, Schneider S, Senges J, Fetsch T, Tebbe U, Willich SN, Stumpf J, Sabin GV, Silber S, Richardt G, Kuck KH (2009) Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry). Am J Cardiol 104:1362–1369PubMedCrossRefGoogle Scholar
  17. 17.
    Ambrose JA, Barua RS (2004) The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 43:1731–1737PubMedCrossRefGoogle Scholar
  18. 18.
    Ishikawa T, Yagi H, Ogawa T, Mori C, Takeda H, Sakamoto H, Mutoh M, Seo A, Shibata T, Yoshida S, Imai K, Horie T, Mochizuki S (2005) Deteriorative effect of smoking on target lesion revascularization after implantation of coronary stents with diameter of 3.0 mm or less. Circ J 69:227–231PubMedCrossRefGoogle Scholar
  19. 19.
    Haddock CK, Poston WS, Taylor JE, Conard M, Spertus J (2003) Smoking and health outcomes after percutaneous coronary intervention. Am Heart J 145:652–657PubMedCrossRefGoogle Scholar
  20. 20.
    Cho L, Bhatt DL, Wolski K, Lincoff M, Topol EJ, Moliterno DJ (2001) Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: pooled analysis from EPIC, EPILOG, and EPISTENT. Am Heart J 141:599–602PubMedCrossRefGoogle Scholar
  21. 21.
    Roy P, Bonello L, de Labriolle A, Okabe T, Pinto Slottow TL, Steinberg DH, Torguson R, Smith K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R (2008) Two-year outcome of patients treated with sirolimus- versus paclitaxel-eluting stents in an unselected population with coronary artery disease (from the REWARDS Registry). Am J Cardiol 102:292–297PubMedCrossRefGoogle Scholar
  22. 22.
    Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP (2006) Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 295:895–904PubMedCrossRefGoogle Scholar
  23. 23.
    Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P, Togni M, Billinger M, Tuller D, Seiler C, Roffi M, Corti R, Sutsch G, Maier W, Luscher T, Hess OM, Egger M, Meier B (2005) Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 353:653–662PubMedCrossRefGoogle Scholar
  24. 24.
    Schomig A, Dibra A, Windecker S, Mehilli J, Suarez de Lezo J, Kaiser C, Park SJ, Goy JJ, Lee JH, Di Lorenzo E, Wu J, Juni P, Pfisterer ME, Meier B, Kastrati A (2007) A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 50:1373–1380PubMedCrossRefGoogle Scholar
  25. 25.
    Sidhu S, Shafiq N, Malhotra S, Pandhi P, Grover A (2006) A meta-analysis of trials comparing Cypher and Taxus stents in patients with obstructive coronary artery disease. Br J Clin Pharmacol 61:720–726PubMedCrossRefGoogle Scholar
  26. 26.
    Ross R (1986) The pathogenesis of atherosclerosis—an update. N Engl J Med 314:488–500PubMedCrossRefGoogle Scholar
  27. 27.
    Fuster V, Badimon L, Badimon JJ, Chesebro JH (1992) The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 326:310–318PubMedCrossRefGoogle Scholar
  28. 28.
    Levine PH (1973) An acute effect of cigarette smoking on platelet function. A possible link between smoking and arterial thrombosis. Circulation 48:619–623PubMedGoogle Scholar
  29. 29.
    Ernst E, Koenig W, Matrai A, Filipiak B, Stieber J (1988) Blood rheology in healthy cigarette smokers. Results from the MONICA project, Augsburg. Arteriosclerosis 8:385–388PubMedGoogle Scholar
  30. 30.
    Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MS (2009) Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 53:1273–1278PubMedCrossRefGoogle Scholar
  31. 31.
    Kotamaki M, Laustiola K, Syvanne M, Heikkila J (1996) Influence of continued smoking and some biological risk factors on restenosis after percutaneous transluminal coronary angioplasty. J Intern Med 240:293–301PubMedCrossRefGoogle Scholar
  32. 32.
    Galan KM, Deligonul U, Kern MJ, Chaitman BR, Vandormael MG (1988) Increased frequency of restenosis in patients continuing to smoke cigarettes after percutaneous transluminal coronary angioplasty. Am J Cardiol 61:260–263PubMedCrossRefGoogle Scholar
  33. 33.
    Myler RK, Topol EJ, Shaw RE, Stertzer SH, Clark DA, Fishman J, Murphy MC (1987) Multiple vessel coronary angioplasty: classification, results, and patterns of restenosis in 494 consecutive patients. Cathet Cardiovasc Diagn 13:1–15PubMedCrossRefGoogle Scholar
  34. 34.
    Holmes DR Jr, Vlietstra RE, Smith HC, Vetrovec GW, Kent KM, Cowley MJ, Faxon DP, Gruentzig AR, Kelsey SF, Detre KM et al (1984) Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 53:77C–81CPubMedCrossRefGoogle Scholar
  35. 35.
    Arora RR, Konrad K, Badhwar K, Hollman J (1990) Restenosis after transluminal coronary angioplasty: a risk factor analysis. Cathet Cardiovasc Diagn 19:17–22PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Mohammad A. Sherif
    • 1
  • Christoph A. Nienaber
    • 2
  • Ralph Toelg
    • 1
  • Mohamed Abdel-Wahab
    • 1
  • Volker Geist
    • 1
  • Steffen Schneider
    • 3
  • Jochen Senges
    • 3
  • Karl-Heinz Kuck
    • 4
  • Ulrich Tebbe
    • 5
  • Gert Richardt
    • 1
  1. 1.Herz-Kreislauf-ZentrumSegeberger Kliniken GmbHBad SegebergGermany
  2. 2.Medizinische Klinik-I, KardiologieUniversitätsklinikum RostockRostockGermany
  3. 3.Klinikum der Stadt Ludwigshafen GmbHStiftung Institut für HerzinfarktforschungLudwigshafenGermany
  4. 4.Medizinische Klinik/KardiologieAsklepios KlinikHamburgGermany
  5. 5.Medizinische Klinik IIKlinikum Lippe-DetmoldDetmoldGermany

Personalised recommendations